| Literature DB >> 11078801 |
A Elnemr1, T Ohta, K Iwata, I Ninomia, S Fushida, G Nishimura, H Kitagawa, M Kayahara, M Yamamoto, T Terada, K Miwa.
Abstract
The aim of this study was to examine whether a specific PPARgamma ligand can inhibit the growth of human pancreatic cancer cells through induction of terminal differentiation. PPARgamma was expressed in five human pancreatic cancer cell lines: Capan-1, AsPC-1, BxPC-3, PANC-1, and MIA PaCa-2. Treatment of these cells with a specific PPARgamma ligand, thiazolidinedione (TZD), resulted in inhibition of both cellular and clonogenic growth, and G1 cell cycle arrest. Finally, thiazolidinedione treatment resulted in induction of p21WAF-1 and increased expression of differentiation markers. These results suggest that thiazolidinedione treatment inhibits growth and induces cellular differentiation in pancreatic cancer cells and thereby reduces their development in favor of differentiated and stable cell phenotype.Entities:
Mesh：
Substances：
Year: 2000 PMID： 11078801 DOI： 10.3892/ijo.17.6.1157
Source DB: PubMed Journal: Int J Oncol ISSN： 1019-6439 Impact factor: 5.650